🇺🇸 FDA
Patent

US 9096602

Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors

granted A61KA61K31/4985A61K45/06

Quick answer

US patent 9096602 (Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors) held by Vertex Pharmaceuticals Incorporated expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Aug 04 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/4985, A61K45/06, A61P, A61P35/00